A surgeon can excise breast cancer from the body, but even the most skilled scalpel may not be able to remove every ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, ...

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.

Sacituzumab govitecan links an anti-Trop-2 antibody to SN-38, one of the chemotherapy drugs used to kill cancer cells in triple-negative breast cancer [3]. Once the drug binds to the cancer cell ...

Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

In a busy reporting day for biotechs, Orthocell reports promising results of a follow-up study of its nerve repair device Remplir.

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

Researchers have found that a cocktail of two cancer drugs can increase the lifespan of mice by up to around 30%, according to a new study. The two drugs, trametinib and rapamycin, were both ...